MS Patients Safely Switch to Gentler Treatment, Study Finds

Multiple sclerosis patients are getting good news: switching from heavy-duty medications to gentler alternatives might work just as well while making life easier and healthier.

A new study from researchers at Raleigh Neurology Associates found that MS patients who moved from high-powered immune therapies to moderate-strength oral medications kept their disease under control. Even better, they cut their infection rates in half.

Dr. John Scagnelli and his team tracked 20 patients who made the switch from anti-CD20 therapies to fumarates, gentler medications taken by mouth. Before switching, 30% of patients experienced relapses during treatment. After the change, only 10% did.

The results got even more encouraging when researchers looked at infections. The annual infection rate dropped by about half after patients switched medications. Hospital stays also decreased by half, including those related to COVID-19.

Brain scans showed similar results too. The same small percentage of patients had new lesions before and after the switch, but the one gadolinium-positive lesion (a sign of active inflammation) appeared only during the stronger treatment, not after.

Why This Inspires

This research matters because it gives doctors and patients more options. Many people with MS face a difficult choice between powerful medications that control their disease and the side effects those medications bring, especially higher infection risk.

The study builds on growing evidence that some patients can safely dial back their treatment once their disease stabilizes. The 2025 Best Practices in Multiple Sclerosis Therapies already recommends considering this approach for older patients dealing with infections or side effects.

Dr. Jennifer Graves from UC San Diego points out that older MS patients often face greater infection risks as their immune systems naturally weaken. The ability to switch to gentler treatments without losing disease control could be life-changing.

Patients chose to switch for various reasons including infection worries, side effects, and personal preference for pills over infusions. The fact that they maintained disease control while improving their health markers validates those choices.

The research started with just 20 patients, but Dr. Scagnelli reports that follow-up analysis now includes over 100 people who made the same switch. More data means doctors will have better guidance for helping patients find the right balance.

For people living with MS, this represents something powerful: the possibility of personalized treatment that adapts to their changing needs while protecting both their neurological health and overall wellbeing.